Modafinil combined with cognitive training: Pharmacological augmentation of cognitive training in schizophrenia

European Neuropsychopharmacology

Volumn 25, Issue 8, 2015, Pages 1178-1189

  Michalopoulou, Panayiota G ^a   Lewis, Shôn W ^b   Drake, Richard J ^b   Reichenberg, Abraham ^a,c   Emsley, Richard ^b   Kalpakidou, Anastasia K ^a   Lees, Jane ^b   Bobin, Tracey ^a   Gilleen, James K ^a   Pandina, Gahan ^d   Applegate, Eve ^b   Wykes, Til ^a   Kapur, Shitij ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Clinical trial; Cognitive impairment associated with schizophrenia (CIAS); Cognitive remediation; Cognitive enhancing drugs; Combination of cognitive enhancing drugs with cognitive training; Modafinil

Indexed keywords

MODAFINIL; PLACEBO; BENZHYDRYL DERIVATIVE; PSYCHOTROPIC AGENT;

ARTICLE; AUDITORY DISCRIMINATION; CLINICAL ARTICLE; COGNITION; COGNITIVE REMEDIATION THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DSM-IV; ELEVATED BLOOD PRESSURE; FEMALE; FUNCTIONAL STATUS; HUMAN; LANGUAGE LEARNING TASK; LEARNING; LETTER MEMORY TASK; MALE; MATRICS CONSENSUS COGNITIVE BATTERY; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MENTAL TASK; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; ROAD TOUR TASK; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SHOPPING TASK; SINGLE DRUG DOSE; TASK PERFORMANCE; VERBAL LEARNING TASK; WECHSLER TEST OF ADULT READING; ADJUVANT CHEMOTHERAPY; ADULT; ADVERSE EFFECTS; CHRONIC DISEASE; COGNITIVE THERAPY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; BENZHYDRYL COMPOUNDS; CHEMOTHERAPY, ADJUVANT; CHRONIC DISEASE; COGNITIVE THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84935851883     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.03.009     Document Type: Article

References (50)

1. Béracochéa D., Celerier A., Borde N., Valleau M., Peres M., Pierard C. Improvement of leprocesses following chronic systemic administration of modafinil in mice. Pharmacol. Biochem. Behav. 2002, 73:723-728.
2. Béracochéa D., Celerier A., Peres M., Pierard C. Enhancement of learning processes following an acute modafinil injection in mice. Pharmacol. Biochem. Behav. 2003, 76:473-479.
3. Breitenstein C., Knecht S. Development and validation of a language learning model for behavioral and functional-imaging studies. J. Neurosci. Method 2002, 114:173-179.
4. Breitenstein C., Wailke S., Bushuven S., Kamping S., Zwitserlood P., Ringelstein E.B., Knecht S. d-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects. Neuropsychopharmacology 2004, 29:1704-1714.
5. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S.E., Leon A.C., Nuechterlein K.H., Laughren T., Levin R., Stover E., Fenton W., Marder S.R. A Summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 2005, 31:5-19.
6. Cacciotti-Saija C., Langdon R., Ward P.B., Hickie I.B., Scott E.M., Naismith S.L., Moore L., Alvares G.A., Redoblado Hodge M.A., Guastella A.J. A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophr. Bull. 2015, 41:483-493.
7. Cain C.K., McCue M., Bello I., Creedon T., Tang D.-I., Laska E., Goff D.C. d-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophr. Res. 2014, 153:177-183.
8. D'Souza D.C., Radhakrishnan R., Perry E., Bhakta S., Singh N.M., Yadav R., Abi-Saab D., Pittman B., Chaturvedi S.K., Sharma M,P., Bell M., Andrade C. Feasibility, safety, and efficacy of the combination of d-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology 2013, 38:492-503.
9. Dahlin E., Neely A.S., Larsson A., Backman L., Nyberg L. Transfer of learning after updating training mediated by the striatum. Science 2008, 320:1510-1512.
10. Davis M.C., Green M.F., Lee J., Horan W.P., Senturk D., Clarke A.D., Marder S.R. Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology 2014, 39:2070-2077.
11. Dawson N., Thompson R.J., McVie A., Thomson D.M., Morris B.J., Pratt J.A. Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity. Schizophr. Bull. 2012, 38:457-474.
12. Dickinson D., Ramsey M.E., Gold J.M. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch.Gen. Psychiatry 2007, 64:532-542.
13. Fisher M., Holland C., Merzenich M.M., Vinogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am. J. Psychiatry 2009, 166:805-811.
14. Floresco S.B., Jentsch J.D. Pharmacological enhancement of memory and executive functioning in laboratory animals. Neuropsychopharmacology 2011, 36:227-250.
15. Foulds J., Stapleton J., Swettenham J., Bell N., McSorley K., Russell M.A.H. Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology 1996, 127:31-38.
16. Gilleen J., Michalopoulou P.G., Reichenberg A., Drake R., Wykes T., Lewis S.W., Kapur S. Modafinil combined with cognitive training is associated with improved learning in healthy volunteers-a randomised controlled trial. Eur. Neuropsychopharmacol. 2014, 24:529-539.
17. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "Right Stuff"?. Schizophr. Bull. 2000, 26:119-136.
18. Hart C.L., Haney M., Vosburg S.K., Comer S.D., Gunderson E., Foltin R.W. Modafinil attenuates disruptions in cognitive performance during simulated night-shift work. Neuropsychopharmacology 2006, 31:1526-1536.
19. Hawkins K.A., Wexler B.E. California verbal learning. Test practice effects in a schizophrenia sample. Schizophr. Res. 1999, 39:73-78.
20. Hunter M.D., Ganesan V., Wilkinson I.D., Spence S.A. Impact of modafinil on prefrontal executive function in schizophrenia. Am. J. Psychiatry 2006, 163:2184-2186.
21. Hyde J.S., Fennema E., Lamon S.J. Gender differences in mathematics performance: A meta-analysis. Psychol. Bull. 1990, 107:139-155.
22. Ingvar M., Ambros-Ingerson J., Davis M., Granger R., Kessler M., Rogers G.A., Schehr R.S., Lynch G. Enhancement by an ampakine of memory encoding in humans. Exp.Neurol. 1997, 146:553-559.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
24. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64:633-647. CATIE Investigators, Neurocognitive Working GroupNeurocognitive Working Group.
25. Keefe R.S., Buchanan R.W., Marder S.R., Schooler N.R., Dugar A., Zivkov M., Stewart M. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far?. Schizophr. Bull. 2013, 39:417-435.
26. Knecht S., Breitenstein C., Bushuven S., Wailke S., Kamping S., Floel A., Zwitserlood P., Ringelstein E.B. Levodopa: faster and better word learning in normal humans. Ann. Neurol. 2004, 56:20-26.
27. Michalopoulou P.G., Lewis S.W., Wykes T., Jaeger J., Kapur S. Treating impaired cognition in schizophrenia: The case for combining cognitive-enhancing drugs with cognitive remediation. Eur. Neuropsychopharmacol. 2013, 23:790-798.
28. Minzenberg M.J., Carter C.S. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
29. Minzenberg M.J., Watrous A.J., Yoon J.H., Ursu S., Carter C.S. Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI. Science 2008, 322:1700-1702.
30. Morgan R.E., Crowley J.M., Smith R.H., LaRoche R.B., Dopheide M.M. Modafinil improves attention, inhibitory control, and reaction time in healthy, middle-aged rats. Pharmacol. Biochem. Behav. 2007, 86:531-541.
31. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of d-Cycloserine and the facilitation of fear extinction and exposure therapy. Biol. Psychiatry 2008, 63:1118-1126.
32. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., Essock S., Fenton W.S., Frese F.J., Gold J.M., Goldberg T., Heaton R.K., Keefe R.S., Kraemer H., Mesholam-Gately R., Seidman L.J., Stover E., Weinberger D.R., Young A.S., Zalcman S., Marder S.R. The MATRICS consensus cognitive battery, Part 1: test selection, reliability, and validity. Am. J. Psychiatry 2008, 165:203-213.
33. Patterson T.L., Goldman S., McKibbin C.L., Hughs T., Jeste D.V. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr. Bull. 2001, 27:235-245.
34. Randall D.C., Viswanath A., Bharania P., Elsabagh S.M., Hartley D.E., Shneerson J.M., File S.E. Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived?. J. Clin. Psychopharmacol. 2005, 25:175-179.
35. Rasetti R., Mattay V.S., Stankevich B., Skjei K., Blasi G., Sambataro F., Arrillaga-Romany I.C., Goldberg T.E., Callicott J.H., Apud J.A., Weinberger D.R. Modulatory effects of modafinil on neural circuits regulating emotion and cognition. Neuropsychopharmacology 2010, 35:2101-2109.
36. Reeder C., Wykes T. Computerised Interactive Remediation of Cognition - Interactive Training for Schizophrenia (CIRCUITS) 2010, King's College London, London.
37. Rosenthal M.H., Bryant S.L. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin. Neuropharmacol. 2004, 27:38-43.
38. Scoriels L., Barnett J., Soma P., Sahakian B., Jones P. Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology 2012, 220:249-258.
39. Scoriels L., Jones P.B., Sahakian B.J. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology 2013, 64:168-184.
40. Spence S.A., Green R.D., Wilkinson I.D., Hunter M.D. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br. J. Psychiatry 2005, 187:55-61.
41. Surti T.S., Corbera S., Bell M.D., Wexler B.E. Successful computer-based visual training specifically predicts visual memory enhancement over verbal memory improvement in schizophrenia. Schizophr. Res. 2011, 132:131-134.
42. Tsanov M., Lyons D.G., Barlow S., González Reyes R.E., O'Mara S.M. The psychostimulant modafinil facilitates water maze performance and augments synaptic potentiation in dentate gyrus. Neuropharmacology 2010, 59:9-19.
43. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., Sahakian B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004, 29:1363-1373.
44. Turner D.C., Robbins T.W., Clark L., Aron A.R., Dowson J., Sahakian B.J. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 2003, 165:260-269.
45. Ward C.P., Harsh J.R., York K.M., Stewart K.L., McCoy J.G. Modafinil facilitates performance on a delayed nonmatching to position swim task in rats. Pharmacol. Biochem. Behav. 2004, 78:735-741.
46. Wechsler D. Wechsler Test of Adult Reading: Examiner's Manual 2001, Texas, San Antonio.
47. Wolinsky F.D., Vander Weg M.W., Bryant Howren M., Jones M.P., Dotson M.M. A randomized controlled trial of cognitive training using a visual speed of processing intervention in middle aged and older adults. PLoS One 2013, 8:e61624.
48. Wong Y., King S., Simcoe D., Gorman S., Laughton W., McCormick G., Grebow P. Open-label, single-dose pharmacokinetic study of modafinil tablets: Influence of age and gender in normal subjects. J. Clin. Pharmacol. 1999, 39:281-288.
49. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 2011, 168:472-485.
50. Wykes T., Reeder C., Landau S., Matthiasson P., Haworth E., Hutchinson C. Does age matter? effects of cognitive rehabilitation across the age span. Schizophr. Res. 2009, 113:252-258.